4DMedical has de-risked the science and reimbursement—now the entire equity story hinges on Philips-led commercialization turning CT:VQ into a new standard of care.
Overview
4DMedical (4DX.AX) is an Australian medtech commercializing a differentiated, non-invasive lung-imaging platform that converts standard radiographic image sequences into **quantitative, four-dimensional ventilation data** (XV Technology). The product suite addresses a diagnostic gap where spirometry and static imaging miss early or regional disease. The company sells primarily via a **SaaS model** (per-scan/subscription), enabling scalability, high margins, and minimal hospital capex because it leverages existing CT/fluoroscopy infrastructure and integrates into PACS and routine protocols. FY2025 operating revenue was ~$5.9M (+56% YoY), with underlying SaaS revenue up ~95%, but losses remain significant (FY2025 net loss ~$30.1M) as commercialization ramps. The portfolio includes XV LVAS, CT LVAS, and the FDA-cleared **CT:VQ** (first non-contrast V/Q imaging solution), expanded by the Imbio acquisition (AI structural analysis for COPD/ILD/PE). The U.S. is the priority market (U.S. VQ opportunity ~US$1.1B). A transformative Philips reseller agreement provides access to ~14,500 CT scanners and meaningful commercialization leverage. After a January 2026 $150M placement, cash exceeds $200M, giving runway to scale adoption and target profitability (potentially ~2028).